Key facts
- This page summarizes Eric Floyd's Form 4 filing for Virpax Pharmaceuticals, Inc. (VRPX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 20 May 2022, 18:12.
Eric Floyd - 18 May 2022 Form 4 Insider Report for Virpax Pharmaceuticals, Inc. (VRPX)
- Reporting relationship
- Director
- Issuer ticker
- VRPX
- Reported as of
- 18 May 2022
- Net transaction value
- +$6,107
- SEC form
- 4
- Accepted by SEC
- 20 May 2022, 18:12:46 UTC
- Prior SEC filing
- 05 Jan 2022
- Next SEC filing
- 04 Jan 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christopher Chipman, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eric Floyd filed Form 4 for Virpax Pharmaceuticals, Inc. (VRPX) on 20 May 2022.
Change
- Previous filing in this sequence was filed on 05 Jan 2022.
- Current net transaction value: +$6,107.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VRPX
transaction
Common Stock, $0.00001 par value
Purchase
- Transaction value
- $6,107
- Shares
- +4,479
- Change %
- +127%
- Price
- $1.36
- Shares after
- 8,018
- Date
- 18 May 2022
- Ownership
- Direct
* marks a reported price that did not pass the local price check.